





Abstract

- 5 The present invention is concerned with compounds of general formula I



- 10 wherein
Z signifies a substituted phenyl, substituted pyridyl, substituted pyrimidyl or substituted indolyl group of formulae a-e



- 15 a , b , c , d and e

- R¹ signifies hydrogen, amino, lower alkylamino, lower dialkylamino, lower alkyl, halogen or trifluoromethyl;
- 20 R² signifies hydrogen or lower alkyl;
- R³ signifies hydrogen, amino, lower alkylamino, lower dialkylamino, lower alkyl, CF₃, lower alkoxy or halogen;
- R⁴ signifies amino, lower alkylamino, lower dialkylamino, lower alkyl, lower alkoxy or halogen;
- 25 R⁵ signifies hydrogen, lower alkylamino, di-lower alkylamino, lower alkoxy or halogen;
- R⁶ signifies lower alkyl, lower alkylamino, di-lower alkylamino, lower alkoxy, halogen or CF₃;
- 30 R⁷ signifies amino, lower alkylamino, di-lower



- alkylamino, lower alkoxy, lower alkylsulphanyl, mercapto, pyrrolidin-1-yl or azetidin-1-yl;
- 5 R⁸ signifies amino, lower alkylamino, di-lower alkylamino, benzylamino, lower alkoxy, lower alkylsulphanyl, halogen, pyrrolidin-1-yl or azetidin-1-yl;
- R⁹ and R¹⁰ each independently signify lower alkoxy or lower alkylamino;
- 10 R¹¹ signifies hydrogen or halogen;
- R¹² signifies hydrogen or lower alkyl, and
- a signifies an optional double bond,
- with the proviso that R⁷ and R⁸ do not simultaneously signify methoxy,
- 15 as well as their pharmaceutically acceptable salts as therapeutically active substances against central nervous disorders and for the production of corresponding medicaments.